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OSM potentiates preintravasation events,
increases CTC counts, and promotes breast
cancer metastasis to the lung
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Joseph Kronz2, Joel R. Garbow3 and Cheryl L. Jorcyk1*
Abstract
Background: Systemic and chronic inflammatory conditions in patients with breast cancer have been associated
with reduced patient survival and increased breast cancer aggressiveness. This paper characterizes the role of an
inflammatory cytokine, oncostatin M (OSM), in the preintravasation aspects of breast cancer metastasis.
Methods: OSM expression levels in human breast cancer tissue samples were assessed using tissue microarrays,
and expression patterns based on clinical stage were assessed. To determine the in vivo role of OSM in breast
cancer metastasis to the lung, we used three orthotopic breast cancer mouse models, including a syngeneic 4T1.2
mouse mammary cancer model, the MDA-MB-231 human breast cancer xenograft model, and an OSM-knockout
(OSM-KO) mouse model. Progression of metastatic disease was tracked by magnetic resonance imaging and
bioluminescence imaging. Endpoint analysis included circulating tumor cell (CTC) counts, lung metastatic burden
analysis by qPCR, and ex vivo bioluminescence imaging.
Results: Using tissue microarrays, we found that tumor cell OSM was expressed at the highest levels in ductal
carcinoma in situ. This finding suggests that OSM may function during the earlier steps of breast cancer metastasis.
In mice bearing MDA-MB-231-Luc2 xenograft tumors, peritumoral injection of recombinant human OSM not only
increased metastases to the lung and decreased survival but also increased CTC numbers. To our knowledge, this is
the first time that a gp130 family inflammatory cytokine has been shown to directly affect CTC numbers. Using a
4T1.2 syngeneic mouse model of breast cancer, we found that mice bearing 4T1.2-shOSM tumors with knocked
down tumor expression of OSM had reduced CTCs, decreased lung metastatic burden, and increased survival
compared with mice bearing control tumors. CTC numbers were further reduced in OSM-KO mice bearing the
same tumors, demonstrating the importance of both paracrine- and autocrine-produced OSM in this process. In
vitro studies further supported the hypothesis that OSM promotes preintravasation aspects of cancer metastasis,
because OSM induced both 4T1.2 tumor cell detachment and migration.
Conclusions: Collectively, our findings suggest that OSM plays a crucial role in the early steps of metastatic breast
cancer progression, resulting in increased CTCs and lung metastases as well as reduced survival. Therefore, early
therapeutic inhibition of OSM in patients with breast cancer may prevent breast cancer metastasis.
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Background
The inflammatory gp130 family of cytokines has been
shown to modulate immune function [1] with important
implications for tumor immunology [2]. Inflammation
and inflammatory cytokines have been associated with
increased breast cancer metastasis and poor survival
rates [3]. Interleukin-6 (IL-6), a well-known inflamma-
tory cytokine in the gp130 family, promotes breast can-
cer metastasis [4]. Other cytokines within the gp130
family also modulate inflammation. One such member,
oncostatin M (OSM), has been associated with a wide
variety of inflammatory disease states, such as in inflam-
matory bowel disease and arthritis [5, 6]. In the context
of cancer, OSM has been shown to induce in vitro ef-
fects associated with cancer invasiveness and to promote
breast cancer metastasis to bone in vivo [7]. In the breast
tumor microenvironment, OSM is produced by breast
tumor cells [8], as well as by stromal cells, including
tumor-associated macrophages and neutrophils [9, 10].
After the secretion of OSM, OSM binds to and accumu-
lates in the extracellular matrix (ECM) in an active form.
This accumulated OSM may then lead to chronic local in-
flammation and increased tumor metastasis [11]. Specific-
ally, it has been shown that human breast tumor cells
signal neutrophils to secrete OSM, which subsequently in-
duces tumor cell vascular endothelial growth factor
(VEGF) production, cell detachment, and invasive capacity
[9]. Collectively, these studies suggest that OSM functions
in breast cancer progression in both an autocrine and a
paracrine fashion.
OSM signaling uses two dimeric receptors. OSM binds
with high affinity to the OSM receptor (OSMR), which
consists of a gp130 subunit and OSMRβ, and with lower
affinity to the leukemia inhibitory factor receptor (LIFR),
which consists of gp130 and LIFRβ [12]. OSMR signal-
ing initiates the JAK/STAT, mitogen-activated protein
kinase (MAPK), and phosphoinositide 3-kinase/AKT
pathways [13, 14], as well as the stress-activated MAPK
p38 and JNK pathways [15]. Whereas OSM binding to
the OSMR has been shown to promote cancer cell ma-
lignancy and reduce long-term survival in patients with
breast cancer [16], LIF activation of the LIFR suppresses
tumor growth and metastasis [17]. Activation of the
LIFR by OSM promotes bone growth and may also sup-
press breast cancer metastatic phenotypes [12, 18].
As a pleiotropic cytokine, OSM appears to play an im-
portant role in promoting breast cancer metastatic po-
tential in vitro while inhibiting breast tumor cell
proliferation [19]. OSM has been shown to function in
breast and various other cancer cells in culture to (1)
promote an epithelial-to-mesenchymal transition (EMT)
and a stem cell-like phenotype [14, 20]; (2) upregulate
expression of proteases such as matrix metalloprotein-
ases [21]; (3) promote tumor cell detachment and
subsequent invasion [22, 23]; (4) induce the expression
of VEGF, hypoxia inducible factor-1α, and other proan-
giogenic factors [24]; and (5) suppress estrogen receptor
(ER)-α expression [16]. Despite increasing in vitro evi-
dence, limited studies have addressed the role of OSM
in breast cancer metastasis in vivo.
Our previous studies were the first to show the im-
portance of OSM in breast cancer metastasis to bone.
Specifically, reduced tumor cell-produced OSM expres-
sion led to a decrease in osteolytic bone metastasis in an
orthotopic 4T1.2 mouse model [7]. Because it has been
demonstrated that OSM functions in normal bone
homeostasis [25], this work suggests an important role
for OSM during postintravasation breast cancer metasta-
sis to bone and subsequent bone destruction. Although
in vitro studies suggest that OSM promotes the early
steps of the metastatic cascade, no existing work differ-
entiates between OSM’s impact on pre- versus postintra-
vasation aspects of the breast cancer metastatic cascade.
The work presented in this paper demonstrates that
OSM initiates the preintravasation steps of the metasta-
sis cascade, increases circulating tumor cell (CTC) num-
bers, promotes lung metastases, and decreases survival
in mice. Conversely, we also show that OSM has no ef-
fect on survival in the postintravasation model that by-
passes the early steps of metastasis by injecting tumor
cells directly into the circulation. Collectively, our work
suggests that therapeutic suppression of OSM in the
tumor microenvironment not only might be an effective
treatment strategy for bone metastasis but also could be




Breast tissue from 72 patients was obtained from paraf-
fin block archives at the Department of Pathology,
Mercy Medical Center, Nampa, ID, USA. Three tissue
microarrays (TMAs) of 1-mm thickness were assessed.
The TMAs were stained for OSM using the Histostain
kit (catalogue number 95-9843; Life Technologies,
Carlsbad, CA, USA) per the manufacturer’s instructions.
The TMAs were deparaffinized and stained overnight
with a 1:400 dilution of rabbit antihuman OSM primary
antibody (catalogue number sc-129; Santa Cruz Biotech-
nology, Dallas, TX, USA) and for 1 hour with 1:1000
goat antirabbit IgG-alkaline phosphatase secondary anti-
body. TMAs stained with secondary antibody alone
served as the negative control, and spleen and salivary
gland served as positive controls for OSM staining. The
TMAs were analyzed in multiple sets of random orders
for OSM expression intensity by a pathologist and were
graded as follows: 0 = no staining; 1 = light staining; 2 =
medium staining; and 3 = dark staining. Grading for each
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patient was averaged for each cell tissue type (ductal epi-
thelial, vessel, stroma). Additional methods are detailed
in Additional file 1: Supplemental Materials and
Methods.
Cell lines and culture conditions
MDA-MB-231-D3H2LN luc2 cells (Caliper Life Sciences,
Waltham, MA, USA) and MDA-MB-231 human breast
cancer cells (American Type Culture Collection, Manas-
sas, VA, USA) were cultured in RPMI 1640 media supple-
mented with 10% FBS and 100 U/ml penicillin-
streptomycin. Cells were maintained at 37 °C, 5% carbon
dioxide, and 95% humidity. 4T1.2 mouse mammary can-
cer cells [26] were cultured in α-minimal essential
medium (α-MEM) supplemented with 10% FBS, 1 mM
sodium pyruvate, and 100 U/ml each of penicillin and
streptomycin, and the cells were passaged for no more
than 6 months. All media and supplements were obtained
from HyClone Laboratories (Logan, UT, USA). All cell
lines were tested for mycoplasma contamination by rou-
tine 4′,6-diamidino-2-phenylindole staining, and experi-
ments were accomplished within ten passages after cell
line thawing.
Plasmid construct design and cell transfection
To transduce MDA-MB-231-Luc2-D3H2LN cells with a
tetracycline (TET)-inducible vector, the full-length OSM
complementary DNA was cloned into the pLenti6.3/TO/
V5-DEST vector (Life Technologies). Lentiviral transduc-
tion of the pLenti6.3/TO/V5-DEST+hOSM vector and
pLenti3.3/TR vector was performed using the Vira-
Power™ II Lentiviral Gateway® Expression System (K367-
20; Life Technologies) in accordance with the manufac-
turer’s instructions. Stably transduced cell lines were
tested for TET induction of hOSM expression by
enzyme-linked immunosorbent assay (ELISA) and West-
ern blot analysis. To create OSM-knockdown 4T1.2
cells, OSM short hairpin RNA (shRNA) and a LacZ
shRNA sequences were cloned into the pSilencer 4.1
plasmid (Life Technologies) and stably transfected into
4T1.2 cells as previously described [7]. Two viable
OSM-knockdown 4T1.2 cell lines were generated using
different shRNA constructs (4T1.2-shOSM1 and 4T1.2-
shOSM2) [7].
ELISA
OSM produced by TET-inducible MDA-MB-231
(MDATO/OSM) cells was tested for in vitro activity.
MDATO/OSM cells were treated with 0.1 mg/ml TET for
48 hours to generate conditioned media (CM)
containing OSM. The CM was then applied to parental
MDA-MB-231, MDA-MB-231-Luc2, or T47D cells for
30 minutes. Respective cell lysates were then collected
from treated cells using PathScan® Sandwich ELISA Lysis
Buffer (catalogue number 7018; Cell Signaling Technol-
ogy, Danvers, MA, USA). The lysates were then run on
a PathScan® Phospho-Stat3 (Tyr705) Sandwich ELISA in
accordance with the manufacturer’s instructions (cata-
logue number 7146; Cell Signaling Technology).
To assess OSM concentration in animal serum, whole
blood was collected from (MDATO/OSM) tumor
xenograft animals at the experimental endpoint and
allowed to coagulate for 30 minutes. The coagulated
blood was centrifuged at 2500 rpm for 10 minutes, and
the upper layer was collected as serum. The serum was
then diluted 1:3 in PBS and used in an hOSM ELISA
(catalogue number DY295; R&D Systems, Minneapolis
MN, USA), which was performed in accordance with the
manufacturer’s instructions.
Western blot analysis
OSM was induced in MDATO/OSM cells for 48 hours
with 0.1 mg/ml TET in 10% FBS RPMI 1640 media. The
CM was collected, run on a gel, and blotted onto 0.22-
μm polyvinylidene difluoride membranes (EMD
Millipore, Billerica, MA, USA). Membranes were
blocked using 5% nonfat dry milk diluted in PBS at
pH 7.4 with 0.05% Tween 20 (NFDM-PBS-T).
Antihuman OSM antibody (catalogue number sc-129;
Santa Cruz Biotechnology) was used at 1:1000 dilution
in 5% NFDM-PBS-T, and a secondary antirabbit horse-
radish peroxidase antibody (catalogue number 711-035-
152; Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) was used at 1:5000 dilution in 5%
NFDM- PBS-T.
Animals and tumor cell injections
All animal experiments were performed in accordance
with the local institutional animal care and use commit-
tee (IACUCs). Six-week-old female athymic nude mice
were used for the xenograft experiments, and 6-week-
old female BALB/c mice were used for the syngeneic
studies. All mice were obtained from the National
Cancer Institute’s Animal Production Facility (Frederick,
MD, USA). OSM-knockout (OSM-KO) BALB/c mice
were backcrossed from OSM-KO C57BL/6 mice, which
were a kind gift from Dr. Peter Donovan, indirectly,
through Dr. James Ihle (St. Jude’s Children’s Hospital,
Memphis, TN, USA). Animals were backcrossed for at
least ten generations, and genotyping was done at each
generation to ensure the presence of the knockout allele.
Nonsurgical orthotopic injections were performed as de-
scribed previously with 2.0 × 106 cells diluted in 50 μl of
PBS containing 10% medium for the xenograft model
and with 1 × 105 cells for the syngeneic models [7]. For
all animals, starting at 2 weeks postinjection, tumor
length and width were measured with mechanical
calipers three times per week, and tumor volume was
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estimated using the equation tumor volume = (length ×
width2)/2. The survival endpoint was defined by the
IACUC as tumor size greater than 20 mm in diameter,
10% or greater weight loss, and/or appearance of
cachexia. At the experimental endpoint, animals were
killed, and their organs were harvested and examined for
any abnormalities. Further analysis specific to each
model is described below.
For peritumoral OSM injections, either 50 μl of PBS
or 1 μg of recombinant full-length human OSM (Pepro-
Tech, Rocky Hill, NJ, USA) diluted in 50 μl of PBS was
injected into the area surrounding the tumor three times
per week until the endpoint of the experiment. When
the tumors became palpable, mice were randomized into
groups and began receiving peritumoral injections.
For the TET-OSM-inducible MDA-MB-231 (MDATO/
OSM) experiments, the OSM-induced group was given
2% sucrose water containing 0.1 mg/ml TET, whereas
the control mice were given just 2% sucrose water until
the endpoint of the experiment. To assess blood platelet
numbers, blood was collected at the endpoint into ethyl-
enediaminetetraacetic acid (EDTA)-coated tubes (BD
Biosciences, San Jose, CA, USA), and a complete blood
count was performed by WestVet Veterinary Clinic
(Garden City, ID, USA).
In vivo bioluminescence imaging and tumor progression
Bioluminescence imaging (BLI) of live animals was initi-
ated at 13 days after cell injection and performed weekly.
Three to five mice were scanned at one time. Ex vivo or-
gans were also scanned using BLI. Both procedures
followed our previously described protocols [27].
Detection of circulating tumor cells by Alu qPCR
The detection of human CTCs in mouse blood was per-
formed as described previously [28]. A human DNA
standard curve was prepared by adding a specified num-
ber of human MDA-MB-231 cells into mouse blood,
and the DNA was then isolated for use in the qPCR re-
actions (Additional file 2: Figure S1). Genomic DNA was
isolated from 100 μl of whole blood collected from mice
at the end of the experiment. DNA was isolated using
the DNeasy Blood & Tissue kit (catalogue number
69581; Qiagen, Hilden, Germany) per the manufacturer’s
standard instructions. DNA concentrations were nor-
malized between each sample, and 4.5 ng of DNA was
added to each 25-μl qPCR reaction. The qPCR reaction
mixture was obtained from the SYBR Green GoTaq
qPCR Master Mix (catalogue number TM318; Promega,
Madison WI, USA), and reaction mixtures were pre-
pared in accordance with the manufacturer’s recommen-
dations. To each reaction, 0.125 μl of 100 μM human
Alu and mouse glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH) primers were added. The primer
sequences are listed in Additional file 1: Table S1. Reaction
conditions were as follows: 50 °C for 2 minutes, 95 °C for
3 minutes, and 40 cycles of (95 °C for 15 minutes, 60 °C
for 30 minutes, and 72 °C for 30 minutes. Fluorescence
measurements were taken during the annealing
temperature stage (60 °C). Cycle threshold (Ct) values
were determined, and the final results were normalized to
mouse GAPDH signal levels to normalize any sample-to-
sample variance in total blood volume and efficiency in
total DNA purification.
Quantitative PCR
For quantitative analysis of lung metastases, lungs dis-
sected from mice bearing mammary tumors were snap-
frozen in liquid nitrogen and pulverized into a fine
powder. DNA was extracted using an NaCl-Tris-EDTA
buffer (100 mM NaCl, 10 mM Tris-HCl, pH 8.0, 1 mM
EDTA) containing 20 μg/ml proteinase K and purified
by two phenol/chloroform (1:1 vol/vol) extractions
followed by ethanol precipitation. The ratio of cancer
cells to normal cells was quantified by measuring the
neomycin resistance gene (neor) DNA levels versus the
vimentin DNA loading control, as described previously
[29]. TaqMan PCR was performed on an Applied
Biosystems 7500 real-time thermocycler (Thermo
Fisher Scientific, Foster City, CA, USA). Probe and pri-
mer sequences are listed in Additional file 1: Table S1.
The cycling conditions were as follows: 50 °C for 5 mi-
nutes, 95 °C for 2 minutes, then 40 cycles of 95 °C for
1 minute and 60 °C for 45 seconds. Fluorescence was
measured every cycle after the annealing step, and Ct
values were calculated. The data were analyzed using the
2−ΔΔCt method [30].
In vivo magnetic resonance imaging
In vivo MRI experiments were performed using a 4.7-T
small-animal magnetic resonance imaging (MRI) scanner
equipped with a DirectDrive™ console (Agilent Tech-
nologies, Santa Clara, CA, USA). The instrument is built
around an Oxford Instruments (Oxford, UK) magnet
containing Magnex (Agilent Technologies, Yarnton, UK)
actively shielded (21-cm inner diameter, ~ 30 G/cm, ~
200 ms rise time) gradient coils driven by International
Electric Company (Helsinki, Finland) gradient power
amplifiers. Respiratory-gated spin-echo MRI studies
were collected using a Stark Contrast (Erlangen,
Germany) 2.5-cm birdcage radiofrequency coil. Prior to
the imaging experiments, mice were anesthetized with
isoflurane and were maintained on isoflurane/O2 (1–
1.5% vol/vol) throughout data collection. The animals’
core body temperature was maintained at 37 ± 1 °C
by circulation of warm air through the bore of the
magnet. During the imaging experiments, the respir-
ation rates for all mice were regular and ~ 2 s− 1.
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Synchronization of MRI data collection with animal
respiration was achieved with a home-built
respiratory-gating unit [31], and all images were col-
lected during postexpiratory periods. The imaging pa-
rameters were as follows: repetition time = 3 seconds;
echo time = 20 milliseconds; field of view = 2.5 cm2;
data matrix = 128 × 128; slice thickness = 0.5 mm;
number of averages = 4. Lung tumors were manually
segmented with ImageJ software (rsbweb.nih.gov/ij;
National Institutes of Health, Bethesda, MD, USA),
and the number and volume of all metastatic tumors
were measured and recorded on an animal-by-animal
basis as described previously [32, 33].
Detection of circulating tumor cells (clonogenic assay)
Colony-forming assays were performed to detect CTCs
in mouse blood. At the endpoint of the animal experi-
ment, whole blood was collected into EDTA-coated
tubes via intracardiac puncture. Red blood cells (RBCs)
were lysed with RBC lysis solution (155 mM NH4Cl,
10 mM KHCO3, 0.1 mM EDTA diluted in double-
distilled H2O) for 4 minutes. The remaining cell mix-
ture, containing white blood cells and CTCs, was spun
down and washed twice with PBS. The cell pellet was
then resuspended in α-MEM with 10% FBS, then plated
and incubated at 37 °C for 7–10 days until colonies
formed. The colonies were then fixed with 10% formalin
in PBS for 15 minutes, stained with Coomassie blue, and
counted.
Epithelial-to-mesenchymal transition assay
4T1.2 mouse mammary cancer cells were plated on a 6-
well plate to a confluence of 30% in α-MEM with 10%
FBS and 1% penicillin-streptomycin. Following a period
of 24 hours to allow cells to adhere, 25 ng/ml recombin-
ant mouse OSM (rmOSM) was added to appropriate
wells. Photomicrographs were taken at a power of 100×
at 24 and 48 hours to observe phenotypic EMT changes
over the 2-day period.
Cell migration assay
4T1.2 cells were plated on 6-well plates to a confluency
of 80% in α-MEM with 10% FBS. After the cells attached
overnight, a straight scratch on the cell monolayer was
made with a sterile 1000-μl polypropylene pipette tip,
and loose cells and debris were washed away with three
sterile PBS washes. The cells were then treated with or
without 25 ng/ml rmOSM and imaged every day for 3
days on the same part of the scratch using negative
phase-contrast microscopy. The images were then
imported into ImageJ software, and raw unmigrated area
was measured by calculating the number of pixels in the
area with no migration. Relative migration intensity was
calculated as migration intensity = (day 0 unmigrated
area/day n unmigrated area) − 1.
Cell detachment assay
4T1.2 mouse mammary cancer cells were plated on 24-
well tissue culture dishes to a confluency of 80% in α-
MEM with 10% FBS. The cells were allowed to attach
overnight, and rmOSM (25 ng/ml; R&D Systems) sus-
pended in α-MEM with 10% FBS was added to the cells.
For up to 8 days, cells that were detached were collected
and counted using a hemocytometer, and viable cells
were detected by lack of trypan blue staining (catalogue
number SV30084.01; HyClone Laboratories).
Statistical analysis
TMA mean staining values were analyzed with repeated
measures in a mixed model framework using compound
symmetric covariance within patients and cancer status
as fixed effects. All other statistical comparisons between
multiple groups were assessed by one- or two-way ana-
lysis of variance (ANOVA) using Tukey’s posttest ana-
lysis. Comparisons between two groups were analyzed
by Student’s t test (two-tailed, unpaired). The statistical
analyses were performed using Prism version 5.0b (Graph-
Pad Software Inc., La Jolla, CA, USA) or SAS version 9.1.3
(SAS Institute, Cary, NC, USA) software. Survival data
were analyzed using the log-rank (Mantel-Cox) test. Sig-
nificance denoted as *p < 0.05, **p < 0.01, and ***p < 0.001.
Results
High OSM expression in ductal carcinoma in situ and
invasive ductal carcinoma suggests autocrine signaling
To assess breast epithelial cell expression and location of
OSM in human breast tumors, TMAs containing samples
from 72 patients were analyzed by IHC. Interestingly,
OSM staining intensity was higher in the ductal carcin-
oma in situ (DCIS) tissue than in normal tissue, whereas
no staining was observed using the control secondary
antibody (Fig. 1a). Representative images of staining inten-
sity are shown in Additional file 3: Figure S2. Quantifica-
tion of OSM levels from all sections showed that the
mean staining intensity for normal adjacent tissue (1.33)
was significantly lower than that of DCIS (2.00) and inva-
sive ductal carcinoma (IDC) (1.66) tissues, whereas meta-
static tissue (1.24) was statistically similar to normal tissue
(Fig. 1b and Additional file 1: Table S2). Fibroblast OSM
expression in the cancerous stroma was significantly lower
(0.39 mean OSM staining) than in adjacent normal stroma
(0.94 mean OSM staining) (p < 0.001) (Additional file 1:
Table S3). Additionally, OSM expression was significantly
higher in patients with metastasis and those with a posi-
tive margin status than in those with a negative margin
status (Additional file 1: Table S4). Similarly to stromal
OSM expression, we found that endothelial cells of blood
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vessels near the cancerous tissue had significantly lower
OSM expression (1.22 mean OSM staining) than the blood
vessel endothelium (1.66 mean OSM staining) around adja-
cent normal tissue (p < 0.001) (Additional file 1: Table S3).
On one hand, breast cancer subtype analysis of IHC
staining revealed that OSM expression increased linearly
with respect to HER2/Neu status in patients with IDC
with increasing HER2/Neu expression (Additional file 1:
Table S4). On the other hand, OSM expression levels
did not change with respect to HER2/Neu in patients
with metastatic disease (Additional file 1: Table S4).
Additionally, OSM expression increased slightly (0.2) for
every 50% increase in the expression of the ER in pa-
tients with IDC but did not change significantly in meta-
static tissue. Together, these results suggest that OSM
protein levels are higher in the earlier stages of breast
cancer and that tumor cell-produced OSM may be im-
portant in autocrine signaling for the promotion of
tumor progression. Although there is some indication
that the expression of OSM is greater in ER+ and
HER2+ breast cancer tissue samples, cell lines repre-
senting these subtypes have poor tumorigenic and
metastatic capacity in vivo [34]. Furthermore, signifi-
cant OSM expression is present in ER− and HER2/
Neu tumors. Therefore, we used metastatic in vivo
models based on the MDA-MB-231-Luc2-D3H2LN
cell line [35] and the highly metastatic 4T1.2 model,
which are both ER−/HER2− [7, 26].
Elevated production of OSM generated from TET-
inducible MDA-MB-231 (MDATO/OSM) cells increases
metastases to lungs and decreases overall survival
In order to assess the effects of cancer cell-produced
OSM in a tumor microenvironment, we developed a sta-
bly transduced triple-negative breast cancer (TNBC)
MDA-MB-231-Luc2-D3H2LN cell line that secretes OSM
in response to TET treatment (+TET;MDATO/OSM).
MDA-MB-231-Luc2-D3H2LN cells have enhanced
Fig. 1 Oncostatin M (OSM) is highly expressed in ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC). a To detect the presence of
OSM in breast cancer tissue, histological microarrays from 72 patients with breast cancer were stained with human OSM antibody by IHC. Twelve
patients had in situ DCIS, 54 patients had nonmetastatic IDC, and 16 patients had IDC with metastasis to lymph nodes (see Additional file 1). The
results showed that normal adjacent tissue expresses little OSM but that OSM is highly expressed in DCIS and IDC. Secondary antibody alone did
not produce any background signals. b Intensity quantification of OSM stained tissues. Mean staining intensity for DCIS (2.00) and IDC (1.66)
tissues was significantly higher than that of normal adjacent tissue (1.33) and metastatic tissue (1.24). There was no statistically significant
difference between normal and metastatic tissue. Multiple cores from the same patients were averaged. Data are expressed as mean ±
SD. *p < 0.05 by one-way analysis of variance with Tukey’s multiple comparisons test
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capacity to metastasize to multiple organs, including lung
and bone, compared with the parental MDA-MB-231
cells, which have poor metastatic capacity via orthotopic
application [35]. To compare the OSM produced by the
MDATO/OSM cells with recombinant human OSM
(hOSM), CM from MDATO/OSM cells treated with TET (0.
1 μg/ml) was collected. MDA-MB-231, MDA-MB-231-
Luc, and T47D breast cancer cells were treated with either
CM from MDATO/OSM cells or with rhOSM (25 ng/ml)
for 30 minutes. OSM signaling was assessed by measuring
STAT3 activation using a pSTAT3 ELISA. For each cell
line investigated, there were no significant differences in
the levels of pSTAT3 induced by OSM produced from
TET-induced MDATO/OSM cells compared with rhOSM
(Fig. 2a, left). Furthermore, the CM from MDATO/OSM
cells treated with TET was assessed on an hOSM
immunoblot, and an expected size band (26 kDa) was
detected (Fig. 2a, middle) by ELISA (Fig. 2a, right),
showing an OSM concentration of 10 ng/ml in the CM.
To assess the activity of MDATO/OSM cells in vivo, 1 ×
106 cells were injected into the fourth mammary fat pad
of female athymic nude mice. The mice were given
drinking water with TET (+TET) or without TET
(−TET) (0.1 mg/ml in 2% sucrose water) to induce OSM
expression in the cancer cells. At the experimental
endpoint, serum was then separated from whole blood,
and serum OSM levels were assessed by ELISA. Tumor-
bearing mice +TET had a 67-fold higher level of OSM
present in their serum than −TET mice (Fig. 2b, left).
Each animal’s physical condition was assessed, and ani-
mals with MDATO/OSM tumors +TET had significantly
increased blood platelet counts (Fig. 2b, center). TET-
treated mice also had a significant decrease in body
weight compared with −TET mice (Fig. 2b, right; Add-
itional file 4: Figure S3A), displaying a prominent spinal
column and reduced apparent body fat, indicative of
cachexia (Additional file 4: Figure S3B). It was previously
reported that cachexia, elevated inflammatory factors,
and kidney disease may be correlated with each other
[36]. In this study, the cachexic animals had kidney ab-
normalities with hypoperfusion and damage to the gross
morphological kidney structures (Additional file 4:
Figure S3C). This correlated with +TET treatment and
high levels of serum OSM in the animals (Additional file 4:
Figure S3D and S3E), suggesting that high OSM levels may
contribute to the development of cachexia and kidney dys-
function. Control animals without tumors treated with
TET had normal body condition and normal kidney
morphology (data not shown).
Additionally, in a separate experiment, animals were
given TET drinking water for only 1 week so that we
could assess the early effects of OSM on metastasis. Ani-
mals receiving 1 week +TET had higher levels of metas-
tases to the lung than −TET mice, as assessed by ex vivo
imaging, (Fig. 2c). Only sporadic spine or liver metasta-
ses were detected at this early time point (data not
shown), which suggests that bone and liver metastases
may grow more slowly or occur as a later event. This re-
sult also suggests that a short-term elevation in the level
of OSM can promote the development of metastases to
the lung. To measure animal survival, mice with
MDATO/OSM tumors were treated with or without TET
and allowed to progress to the endpoint. Mice given
+TET drinking water had a mean decreased survival of
11 days compared with −TET mice (Fig. 2d).
Collectively, these results demonstrated that elevated
levels of tumor cell-produced OSM led to increased lung
metastases, decreased survival, and deterioration in body
condition indicative of cachexia.
OSM increases lung metastases and circulating tumor cell
numbers in an orthotopic MDA-MB-231 model of breast
cancer
To assess the paracrine effects of OSM, exogenous OSM
was injected peritumorally in an orthotopic MDA-MB-
231 xenograft model. In this model, 2 × 106 MDA-MB-
231-Luc2-D3H2LN cells were injected into the fourth
mammary fat pads of female nude mice. After the tu-
mors were palpable (~ 3 mm), OSM (1 μg in 50 μl of
PBS) or PBS alone was injected peritumorally three
times per week, and mice were monitored until the end-
point criteria were met. Peritumoral injections can po-
tentially cause supraphysiologic concentrations of OSM
in the local tumor microenvironment, which may amp-
lify any effect that OSM has on the tumor. However, in
light of recent data suggesting that OSM accumulates in
the acidic ECM, actual concentrations of inflammatory
cytokines in the tumor microenvironment may be much
higher locally than previously thought [11, 37]. Unex-
pectedly, tumor volume did not differ between the
groups (Fig. 3a), even though OSM has been shown to
reduce MDA-MB-231 cell proliferation in vitro [38].
The BLI intensities of the tumors from both groups were
similar (Fig. 3b), although a few mice in each group had
lower BLI intensities owing to tumor necrosis.
Mice receiving peritumoral OSM showed larger meta-
static volumes in both lung and spine than mice receiv-
ing PBS, as assessed by ex vivo imaging (Fig. 3c, left).
Additionally, lungs dissected from the OSM-injected
group had BLI intensities that were two orders of magni-
tude (102) higher than those in the PBS-injected group
(Fig. 3c, right). Similarly, spinal BLI intensity from
OSM-treated mice averaged 2 × 107 photons/second,
whereas control mice had a mean signal of 3 × 105
photons/second.
In patients with advanced and/or inflammatory breast
cancer, high numbers of CTCs have been detected, sug-
gesting a correlation between inflammatory factors and
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Fig. 2 (See legend on next page.)
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Fig. 3 Peritumoral oncostatin M (OSM) injections into mice with MDA-MB-231-D3H2LN tumors promote the development of metastases and circulating
tumor cells (CTCs). a The timeline shows orthotopic MDA-MB-231-D3H2LN human breast tumor cell injection at day 0, peritumoral OSM or PBS injections
beginning three times per week at day 13, and the final day of killing of both groups at day 61. Average tumor volume (mm3) did not differ between
the peritumorally injected OSM and PBS control groups. b Representative images of PBS- and OSM-injected tumor-bearing mice imaged ventrally
by bioluminescence imaging (BLI). There was no statistically significant difference between the groups. c Left: Representative ex vivo BLI
study of lungs and spine from mice bearing MDA-MB-231-D3H2LN Luc2 tumors that were treated with peritumoral injections of PBS or
OSM. Right: Ex vivo BLI intensities were quantified in the lung and spine. Lungs from mice receiving peritumoral OSM injections showed
a 37.9-fold higher BLI intensity than those with PBS injections, and spines from mice injected with OSM showed an approximately 25.9-
fold increase over mice that received PBS injections. Data are expressed as photons/second (mean ± SEM; n = 5–6). d Human CTCs containing
human Alu DNA were detected in mouse blood by qPCR. In animals that received OSM injections, there was a fourfold increase in the number of CTCs
compared with controls. Data are expressed as mean ± SEM *p < 0.05 by two-tailed t test
(See figure on previous page.)
Fig. 2 Oncostatin M (OSM) produced by tetracycline (TET)-inducible MDA-MB-231 (MDATO/OSM) cell MDATO/OSM) tumors increase metastasis and
decrease survival. a MDATO/OSM human breast cancer cells were treated with (+TET) or without TET (−TET), and the resultant conditioned media
(CM) from the treated cells were applied to parental MDA-MB-231, MDA-MB-231-LUC, and T47D cells. Left: The activity of OSM accumulated in
the CM was compared with commercially obtained recombinant human OSM (rhOSM) (25 ng/ml). There was no significant difference between
OSM produced by MDATO/OSM versus rhOSM versus its ability to induce pSTAT3. Middle: Western blot analysis depicting that CM produced by
MDATO/OSM cells stimulated with TET contain OSM. Right: Enzyme-linked immunosorbent assay (ELISA) analysis showed that CM from TET-treated
MDATO/OSM cells contain 10.1 ng/ml of hOSM. b Left: Animals with MDATO/OSM tumors were given drinking water with or without TET, and whole
blood was collected at the experimental endpoint. After allowing the blood to clot and serum was separated by centrifugation, the resultant
serum OSM levels were measured by ELISA. Animals with MDATO/OSM tumors with drinking water containing TET had 67-fold higher serum OSM
levels. Center: Platelet counts were higher in +TET MDATO/OSM tumor-bearing mice than in −TET mice. Right: +TET MDATO/OSM tumor-bearing mice
had lower body weight than −TET mice. c Animals with MDATO/OSM tumors were given drinking water containing TET for 1 week, and their lung
metastasis levels were assessed by ex vivo bioluminescence imaging. Left: Representative ex vivo bioluminescence image. Right: Average radiance
analysis of the ex vivo bioluminescence imaging in photons per second per square centimeter per square radian (p/s/cm2/sr). Animals with
MDATO/OSM tumors +TET had a fivefold higher bioluminescent radiance than −TET mice (−TET, n = 3; +TET, n = 6). Data are expressed as mean ±
SEM. d Kaplan-Meier survival curve for mice with MDATO/OSM tumors ± TET. Mice that did not receive TET survived, on average, 11 days longer
(−TET, n = 9; +TET, n = 10). ***p < 0.001 by log-rank test. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 by two-tailed t
test or one-way analysis of variance with Tukey’s posttest where appropriate
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the number of CTCs [39]. In our xenograft model, both
human MDA-MB-231-Luc2 tumor cells and potential
CTCs contained multiple copies of human Alu DNA re-
peat sequences. To assess CTC numbers, DNA was iso-
lated from mouse blood, and the levels of human Alu
DNA repeat sequences were determined in the blood by
qPCR. The resultant Ct values were fitted to the stand-
ard curve to determine total CTC numbers in each sam-
ple (Additional file 2: Figure S1). In animals that
received rhOSM injections, there was a fourfold increase
in the number of CTCs per 100 μl of mouse blood com-
pared with animals that did not receive OSM (Fig. 3d).
Collectively, this suggests that increased paracrine OSM
in the tumor microenvironment increases metastasis to
lung and spine while also increasing CTCs.
Suppression of OSM in a syngeneic mouse model
reduced lung metastases
To use an immunocompetent mouse model, we
employed two highly metastatic 4T1.2 mouse mammary
tumor cell lines exhibiting knockdown expression of
OSM in a syngeneic, orthotopic model of breast cancer
[7]. These two independent cell lines (4T1.2-shOSM1
and 4T1.2-shOSM2), developed from two independent
shRNA constructs, were shown by ELISA to secrete a 3-
to 12-fold reduction in OSM, respectively, compared
with control 4T1.2-LacZ cells [7]. To test the effects of
OSM on mammary tumor metastasis in vivo, 1 × 105
control 4T1.2-LacZ, 4T1.2-shOSM1, and 4T1.2-
shOSM2 cells were injected orthotopically into the
mammary fat pads of female BALB/c mice.
The mean number of relative lung metastases was
shown to be tenfold lower in mice that received 4T1.2-
shOSM1 cells and fivefold lower in mice injected with
4T1.2-shOSM2 cells compared with 4T1.2-LacZ control
cells (Fig. 4a). Histology performed on tissues from mice
injected with parental 4T1.2 cells using an antimouse
OSM antibody showed strong OSM expression in the
primary mammary tumor, as well as some background
expression in the normal breast connective tissue
(Additional file 5: Figure S4). Specifically, very high
OSM expression was seen at the leading edge of the pri-
mary mammary tumor, in closest proximity to the breast
stroma.
Fig. 4 Reduced oncostatin M (OSM) expression results in fewer spontaneous lung metastases and lower total volume of lung metastases by
magnetic resonance imaging (MRI). a Lung metastasis burden was quantified by qPCR. Mice bearing mammary 4T1.2-shOSM1 or 4T1.2-shOSM2
tumors had less metastasis to the lung than mice with 4T1.2-shLacZ tumors. b Mice bearing 4T1.2-shOSM2 tumors had less metastatic lesions in
the lung as detected by MRI at the endpoint of the experiment than mice bearing parental 4T1.2 or control 4T1.2-shLacZ tumors. MRI quantification of
lung metastatic volume (c) and total number of lung metastases (d) showed significantly higher volume and number of lung metastases in the 4T1.2-
or 4T1.2-shLacZ-injected mice than the 4T1.2-shOSM2-injected mice (4T1.2, n = 6; 4T1.2-shLacZ, n = 7; 4T1.2-shOSM2, n = 7). Data are expressed as
mean ± SEM. *p < 0.05 and **p < 0.01 by one-way analysis of variance with Tukey’s multiple comparisons test
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MRI was used to track lung metastasis progression in
vivo after injection of parental 4T1.2, control 4T1.2-
shLacZ, and 4T1.2-shOSM2 cells. Mice were scanned
postinjection at days 20–21, days 25–26, and just before
being killed at days 29–30 (Fig. 4b). For all three cell
lines, MRI studies showed essentially no detectable
metastasis at days 20–21. However, at 25–26 days and
29–30 days, readily identifiable metastases were ob-
served in lung images. The average metastasis volume
was significantly decreased, by 50–80%, in 4T1.2-
shOSM2 cells compared with 4T1.2-shLacZ control or
parental 4T1.2 cells, respectively (Fig. 4c). There were
also significant differences between the parental 4T1.2
cells and the control 4T1.2-shLacZ cells, which may be
due to the potential off-target effects of shRNA activa-
tion [40–42]. This highlights the importance of using a
true nontargeting shRNA control such as the 4T1.2-
shLacZ cells because shRNA activation alone appears to
have cell-static effects in cancer cells [40].
Further analysis revealed that the total number of me-
tastases was also reduced by more than 50% in mice
injected with 4T1.2-shOSM2 cells compared with con-
trol 4T1.2-shLacZ cells at 25–26 days and 29–30 days
(Fig. 4d). Thus, in vivo MRI confirmed that OSM may
be a potent inducer of the metastatic cascade that results
in lung metastases originating from a primary mammary
tumor. In sum, these results suggest that OSM is neces-
sary for spontaneous mammary tumor metastasis to the
lung in a syngeneic mouse model.
Suppression of OSM by shRNA increases survival from
spontaneous metastasis via orthotopic injection but not
via intracardiac injection in vivo
We used a tumor resection survival model to mimic sur-
gical removal of the primary tumor in patients and to
determine if suppression of tumor-produced OSM limits
early metastases. Orthotopic mammary fat pad injections
were performed using control 4T1.2-shLacZ cells, 4T1.
2-shOSM1 cells, and 4T1.2-shOSM2 cells. Primary tu-
mors were resected when they became palpable at day
14 (Fig. 5a), and mice were monitored until endpoint
criteria were met (see the Methods section above). The
mean survival time of the mice that received 4T1.2-
shOSM1 and 4T1.2-shOSM2 cell injections significantly
increased, by 5 and 10 days, respectively, compared with
animals with 4T1.2-shLacZ tumors (Fig. 5a). These re-
sults suggest that following primary mammary tumor re-
section, decreased OSM expression in primary tumor
cells leads to increased survival.
In order to determine if OSM affects postintravasation
aspects of metastasis, we injected the mammary tumor
cells directly into the circulatory system via the left ven-
tricle of the heart. There was no statistical difference in
the survival time between mice injected intracardially
with 4T1.2-shLacZ versus 4T1.2-shOSM2 cells (Fig. 5b).
Similarly, there was no statistical difference in lung
metastatic burden in the two different tumor types as
assessed by qPCR (Additional file 6: Figure S5). These
results suggest that tumor cell OSM expression has little
effect on the postintravasation aspects of metastasis to
lung, such as extravasation and metastatic site
implantation.
CTC number and metastatic burden is reduced in OSM-
knockout mice compared with wild-type mice
To determine if knocking out OSM in the whole organ-
ism affects CTC numbers in the 4T1.2 mouse model,
wild-type and OSM-KO BALB/c mice were orthotopi-
cally injected with either 4T1.2-shLacZ or 4T1.2-
shOSM2 cells. Whole blood was collected at the end-
point, RBCs were lysed, and the remaining white blood
cells containing the epithelial CTCs were examined
using a clonogenic assay (Fig. 5c). Blood from control
mice with no tumors had no colony formation
(Additional file 7: Figure S6). Blood from OSM-KO mice
injected with 4T1.2-shOSM2 cells had 15-fold fewer
CTCs and 2.5-fold fewer lung metastases than wild-type
mice injected with control 4T1.2-shLacZ cells (Fig. 5d,
left). Additionally, OSM-KO mice bearing 4T1.2-shLacZ
tumors had 10-fold fewer CTCs and 2.5-fold fewer lung
metastases than wild-type mice with the same tumor
type (Fig. 5d, right). In a separate in vitro assay to test
the level of colony formation, there were no differences
in colony numbers between the cell lines when seeded at
low numbers (~ 10 cells) (Additional file 8: Figure S7),
which indicates that the OSM-knockdown cells do not
have reduced ability to survive and develop colonies.
These results suggest that microenvironment OSM, in-
dependent of tumor cell-secreted OSM, has a large ef-
fect on tumor cell dissemination into the circulation.
Furthermore, this highlights the importance of paracrine
OSM in breast cancer progression and metastasis.
OSM increases preintravasation metrics of metastatic
capacity in 4T1.2 cells
For tumor cells to enter the bloodstream as CTCs and
subsequently metastasize, it is thought that they must
first undergo EMT, followed by detachment, migration,
and intravasation into the circulatory system [43]. Al-
though OSM has been shown to increase tumor cell de-
tachment and migration and to induce EMT in human
breast cancer cell lines [16, 20–22, 44], no data have
been published on murine 4T1.2 cells in relation of
OSM’s in vitro effects. TNBC (ER−, PR−, HER2−) 4T1.2
mouse mammary cancer cells were treated with OSM
(25 ng/ml) for 24 to 48 hours. On one hand, because
4T1.2 cells are an aggressive mesenchymal mammary
cancer cell type, OSM did not affect cell morphology or
Tawara et al. Breast Cancer Research  (2018) 20:53 Page 11 of 18
produce an EMT in vitro (Fig. 6a). On the other hand,
OSM significantly increased 4T1.2 mammary tumor
cell migration 7-fold by day 3 in a cell migration
assay (Fig. 6b) and tumor cell detachment 100-fold by
day 8 (Fig. 6c). Our previous studies also
demonstrated that OSM increases overall invasive po-
tential in 4T1.2 cells [7]. These increases in migration
and detachment were seen despite a 20% inhibition
by OSM on 4T1.2 cell proliferation (Additional file 9:
Figure S8). Together, these results suggest that OSM
Fig. 5 Reduced tumor cell oncostatin M (OSM) expression increases survival in a 4T1.2-shOSM mouse model of tumor resection. a Timeline shows
orthotopic mouse mammary tumor cell injection at day 0, resection at day 14, and final day of killing per group (ranging from 35 to 72 days). Kaplan-
Meier survival analysis following tumor resection showed that mice bearing 4T1.2-shOSM1 or 4T1.2-shOSM2 tumors had significantly increased survival
compared with mice with control 4T1.2-shLacZ tumors. *p < 0.05 by log-rank test. b Timeline shows intracardiac mammary tumor cell injection at day
0 and final day of killing (days 21 to 22). Kaplan-Meier survival analysis showed no difference in survival between mice injected with control 4T1.2-
shLacZ and those injected with 4T1.2-shOSM2 cells. c Blood was collected from wild-type and OSM-knockout (OSM-KO) animals with 4T1.2-shOSM2 or
control tumors, and circulating tumor cell (CTC) counts were assessed via a colony-forming assay. Representative image depicts higher numbers of
colonies that formed from the blood collected from wild-type mice with control tumors. d Left: Quantification of the colony-forming assay
showed that wild-type animals bearing 4T1.2-shOSM2 tumors had a 15-fold lower number of CTCs than the animals bearing control
4T1.2-shLacZ tumors. Furthermore, OSM-KO mice with 4T1.2-shLacZ tumors had 10-fold less CTCs than wild-type mice bearing the same
cells. Right: Wild-type mice bearing 4T1.2-shOSM2 tumors had a 2.5-fold lower number of lung metastases than mice with control 4T1.2-
shLacZ tumors. OSM-KO mice bearing 4T1.2-shLacZ or 4T1.2-shOSM2 tumors had 2- to 2.5-fold less lung metastases than wild-type mice
(4T1.2-shLacZ, n = 8–9; 4T1.2-shOSM1, n = 7; 4T1.2-shOSM2, n = 9–12). Data are expressed as mean ± SEM. *p < 0.05 and ***p < 0.001 by
one-way analysis of variance with Tukey’s multiple comparisons test
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may promote tumor cell dissemination into the circula-
tion by increasing cell migration and detachment, which
may subsequently increase the number of CTCs.
Discussion
In this paper, we show that OSM, whether acting in a
paracrine fashion or produced by breast tumor cells and
acting in an autocrine manner, can potentiate preintrava-
sation metastatic events, such as migration, detachment,
and increased CTCs (Fig. 7). Recent studies suggest that
cells from DCIS can actually metastasize prior to their
development into malignant IDC, though what triggers
this early event has not been well characterized [45].
Our breast cancer IHC studies using TMAs resulted in
an intriguing finding: OSM expression is highest in the
epithelium of DCIS, as compared with IDC, metastatic,
or adjacent normal tissue, though OSM levels in IDC
are also high. When looking at the adjacent stroma, we
found reduced levels of OSM in the fibroblasts and
blood vessels of IDC tissues compared with normal
Fig. 6 Oncostatin M (OSM) promotes 4T1.2 cell detachment and migration. a 4T1.2 mouse mammary cancer cells were plated and treated with
recombinant murine OSM (25 ng/ml) for 24 and 48 hours. No morphological changes indicative of epithelial-mesenchymal transition were detected. b
4T1.2 cells were grown to 80% confluence, and a uniform scratch was made. Cells treated with OSM had higher levels of migration than untreated
controls (sevenfold by day 3). c A detachment assay was performed on 4T1.2 cells, and the number of detached cells was quantified. Cells treated with
OSM had significantly higher numbers of detached cells (100-fold at day 8). Data are expressed as mean ± SEM. *p < 0.05 and ***p < 0.001 by
two-tailed Student’s t test
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tissue. On one hand, this is interesting because we have
previously shown that secreted OSM binds to proteins
of the ECM and bioaccumulates in the tumor’s acidic
microenvironment [11]. On the other hand, García-
Tuñón et al. observed higher levels of breast tissue OSM
and OSMR in IDC than in DCIS or normal tissue [8].
Although this finding differs somewhat from our study
in relation to the stage at which the highest level of
OSM was seen, there is agreement that higher OSM
levels were detected in cancerous tissue than in normal
tissue.
In this study, three different TNBC mouse models
were used: One was an immunocompetent BALB/c
model using syngeneic 4T1.2 cells, and two were im-
munosuppressed athymic xenograft mouse models,
using either MDA-MB-231-Luc2 or MDATO/OSM cells.
Despite the differences between the systems used in our
study, our results were consistent in that suppression of
OSM reduced metastasis in BALB/c mice and injection
of recombinant hOSM or TET-induced hOSM expres-
sion in MDATO/OSM cells increased human breast tumor
metastasis in athymic mice. Although adaptive immunity
is stunted in athymic mice owing to nonfunctional T
cells, innate immune function is still intact [46]. Recent
studies indicate that innate immunity plays a primary
role in controlling progression of tumor growth and
metastatic disease [47], and innate immune cells such as
macrophages home to hypoxic tumors and promote
angiogenesis [10]. OSM has recently been shown to
increase the tissue infiltration of both the
proinflammatory M1 and the wound-healing M2 macro-
phages [48]. Specifically, Lauber et al. demonstrated that
OSM promotes lung metastatic burden in melanoma
through M2 macrophage infiltration [49]. Thus, OSM
may be promoting prometastatic responses, mediated by
innate immunity, in the tumor microenvironment of
both athymic and BALB/c mouse models to promote
metastases.
Although the traditional cause of mortality in patients
with advanced cancer is metastasis to vital organs, cach-
exia has been shown to contribute up to 50% of cancer
patient deaths [50]. Significant weight loss as a conse-
quence of fat loss and muscle wasting, indicative of
cachexia, was seen in our TET-induced OSM in
MDATO/OSM xenograft mouse model. TET alone does
not appear to have any effect on kidney function [51].
Interestingly, TET has been shown to actually reduce
tumor cell growth and aggressiveness [52], but this
effect was not seen in our studies. Other studies have
shown that high levels of various inflammatory
cytokines, such as IL-6, potentiate loss of adipose tissue
and muscle wasting [53]. Therefore, OSM may be yet
Fig. 7 Model of oncostatin M (OSM)-mediated metastasis. OSM is produced in an autocrine fashion by tumor cells (a), as well as by tumor-associated
macrophages and neutrophils (b), for paracrine signaling. OSM promotes preintravasation effects, such as tumor cell detachment and migration, that
can drive tumor cell intravasation into the circulation to develop circulating tumor cells and eventually metastasis. c When tumor cells are injected
directly into the circulatory system, they bypass the multistep preintravasation aspects of metastases, and our data suggest that OSM has
little effect on their extravasation and colonization at a secondary site
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another cytokine that could exacerbate cachexia in pa-
tients with breast cancer. In this study, mice with 4T1.2-
shOSM1 tumors had the lowest lung metastatic burden
despite the fact that 4T1.2-shOSM2 cells have lower
OSM expression [7]. However, this reduced lung metas-
tasis in 4T1.2-shOSM1 tumor-bearing mice did not
translate to increased survival for 4T1.2-shOSM2
tumor-bearing mice. This supports the notion that meta-
static burden may not be the only cause of increased
mortality, but that elevated cytokine levels may contrib-
ute to reduced survival. Furthermore, because cytokines
modulate the immune system, it is very probable that
cancer cachexia is related to maladaptive immune re-
sponses [54]. Interestingly, there were also major differ-
ences between the parental 4T1.2 cells and the control
4T1.2-shLacZ cells, where the shLacZ cells had signifi-
cantly reduced lung metastasis volume. This highlights
the importance of using a nontargeting shRNA control
cells because shRNA activation has been known to have
multiple off-target effects leading to reduced cell sur-
vival, metastasis, and growth [40–42, 55].
Platelets, as an adjunct to their classical role in throm-
bosis, are also important in mediating inflammation and
immune response [56]. We found that in the MDATO/
OSM mouse model, higher OSM levels were correlated
with increased platelet counts and reduced animal
survival. Previous studies in patients with breast cancer
have shown that elevated platelet counts were associated
with poor prognosis and reduced disease-free survival
[57]. Platelets have also been implicated in the promo-
tion of metastasis by acting as a reservoir for factors that
induce invasion and function to protect CTCs from the
immune system [58]. In our study, increased viable
CTCs were detected in our mouse models when higher
levels of OSM were present, which may have been due
to the elevated levels of platelets in circulation.
The ability of tumor cells to intravasate into the circu-
lation directly correlates with CTC numbers from the
corresponding tumor [59]. Increased CTC numbers have
been linked clinically to enhanced metastatic burden in
patients and a reduced 5-year survival rate [60]. Because
tumors may shed early during cancer development [61],
the detection of CTCs would be an important tool in
the clinic to assess the metastatic capacity of a tumor,
even as early as in precancerous DCIS. Typically, CTCs
are detected using cancer epithelial markers, such as
cytokeratins 18/19 [62]. However, highly aggressive
tumor cells that have already undergone EMT, and thus
have lost their epithelial markers, may evade detection
[63]. Other possibly viable markers for CTC detection
include epithelial cell adhesion molecule and human
mammaglobin A [62]. For our studies, the highly aggres-
sive mesenchymal-like MDA-MB-231 cells show nega-
tive or low expression for each of these markers, making
conventional CTC detection unfeasible [63]. Thus, we
employed multiple techniques that are marker-
independent, such as the colony-forming assay for the
mouse mammary tumor model or a PCR assay targeting
human Alu sequences in the human breast tumor
model. We did not use the colony-forming assays to as-
sess the human breast tumor model, because the MDA-
MB-231 cells have a highly variable in vitro survival rate
when seeded at low numbers. 4T1.2 cells showed no dif-
ference in the overall level of cell survival when seeded
at low numbers in vitro, which makes the colony-
forming assay ideal for the 4T1.2 tumor model.
In our studies, suppression of tumor-produced OSM
or the absence of OSM in OSM-KO mice resulted in re-
duced numbers of CTCs, whereas injection of recombin-
ant OSM increased CTCs. There was no significant
difference in the number of CTCs with or without TET
in the MDATO/OSM mouse metastasis model (data not
shown). This suggests that paracrine OSM may be more
important than autocrine-produced OSM for CTC de-
velopment. Indeed, in our OSM-KO mouse model,
where there is less paracrine OSM, total CTC numbers
and lung metastatic burden were significantly reduced
compared with WT mice. Although the number of
CTCs appeared modest in our study, these numbers are
actually higher than the low numbers of CTCs seen in
previously published studies [64, 65]. It has been re-
ported that even in advanced cancers, there can be as
few as 1–5 CTCs per 7.5 ml [66]. Our higher CTC num-
bers may point to differences in human and mouse
physiology and may explain the much more rapid pro-
gression of metastatic disease seen in mice than in
patients.
To assess some of the early aspects of metastasis that
could lead to generation of CTCs in vitro, tumor cell
EMT, migration, and detachment were studied in the
highly aggressive 4T1.2 tumor model. 4T1.2 mammary
tumor cells, which are considered analogues of high-
grade human TNBC, have already undergone EMT, and
OSM did not cause additional EMT-like effects [67].
However, our results show that OSM does increase cell
migration, detachment, and invasion in 4T1.2 cells [7],
supporting the idea that OSM operates in the preintra-
vasation steps of metastasis. Other OSM-related factors,
such as IL-6 and IL-8, may promote CTCs by increasing
tumor cell invasion, detachment, and EMT [68]. Fur-
thermore, these effects may be amplified in vivo because
OSM possesses a proclivity to accumulate in the acidic
ECM of the tumor microenvironment [11].
On the basis of our findings, OSM may potentiate the
preintravasation aspects of the metastatic cascade to in-
crease metastasis to the lung and bone [7]. This is evi-
denced by the fact that intracardiac injection of 4T1.2
cells with reduced OSM (4T1.2-shOSM2) into mice,
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which bypasses the intravasation step of the metastatic
cascade, did not result in increased survival compared
with control cells (4T1.2-shLacZ). Therefore, it is highly
probable that OSM functions before intravasation during
cancer progression and suggests that OSM does not
affect CTC survival, tumor cell extravasation, and/or
secondary tumor growth.
Conclusions
The results of this study suggest that OSM increases
lung metastases and CTC numbers by acting on early
metastatic events (Fig. 7). Specifically, OSM increases
tumor cell migration, detachment, and invasion [7], sup-
porting the idea that OSM operates in the preintravasa-
tion steps of metastasis. Inhibition of OSM and/or
OSMR has demonstrated antitumor effects and has re-
cently been receiving increased attention as a possible
cancer therapy [69, 70]. However, to our knowledge, no
small-molecule inhibitors or humanized antibodies that
target OSM signaling are in clinical trials for metastatic
breast cancer. Taken together, the findings of this study
provide a rationale for the administration of anti-OSM
therapeutics before tumor resection, at the earlier stages
of the disease, when the potential to improve overall sur-
vival of patients with breast cancer is greatest.
Additional files
Additional file 1: Table S1. Primer and probe sequences used for qPCR
assay for the detection of CTC in blood obtained from tumor-bearing mouse.
Table S2. Table format data for Fig. 1B show total number of patients and
cores for each stage of breast tissue assessed. Table S3. Mean expression
levels are statistically significantly different among cancerous and normal
tissues for both stroma and blood vessel endothelium (p<.001). Table S4.
Margin status, Her2/neu status and estrogen receptor (ER) status, were
revealed by repeated measures analysis. Mean expression levels are statisti-
cally significantly different among cancerous, normal, and metastatic tissues
for margin status, and ER status. For Her2 status, significant differences were
found among cancerous, normal and between 0 and 1 staining intensity for
metastatic tissues (p<.001). (DOCX 343 kb)
Additional file 2: Figure S1. qPCR standard curve derived from spiking
cancer cells into mouse blood. MDA-MB-231 cells were spiked into
mouse blood, and DNA was extracted and subjected to qPCR ana-
lysis. Specific cell numbers were correlated to CT values and were
used to construct a standard curve for the CT values extrapolated
from experimental mouse blood. (PPTX 186 kb)
Additional file 3: Figure S2. Representative OSM staining intensity in
IHC. 0 = no staining (image not shown), 1 = light staining, 2 = moderate
staining, 3 = heavy staining. (PPTX 27 kb)
Additional file 4: Figure S3. Deterioration of physical condition in
MDATO/OSM tumor-bearing mice treated with TET. a MDATO/OSM tumor-
bearing mice treated with tetracycline (+TET) lost, on average, 11.4% of
their body weight during TET treatment, compared with −TET mice,
which gained an average of 5.5% of their body weight over the same
period. b Representative image of mice with MDATO/OSM tumors +TET
shows prominent spinal column, muscle wasting, and lack of visible
adipose tissue. c Gross morphology of normal (left) and abnormal
kidneys (right). Normal kidneys have a distinct border between the
medulla and the cortex, with the cortex shown in a darker pink/red color
and the medulla shown in a lighter pink color. This indicates that normal
blood perfusion was taking place. Abnormal kidneys were either both
pale and hypoperfused (middle) or damaged (right), with no clear
distinction between the cortex and the medulla. d One hundred percent
of mice in the +TET group have abnormal kidney morphologies, whereas
only 25% of the mice in the −TET group have abnormal kidneys. **p <
0.01 by Fisher’s exact test. e Sera from mice with abnormal kidneys have
a statistically significant higher level of OSM than sera from mice with
normal kidneys. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01,
and ***p < 0.001 by two-tailed Student’s t test. (ZIP 135 kb)
Additional file 5: Figure S4. OSM is highly expressed in orthotopic
4T1.2 primary mammary tumors in female BALB/c mice. Histology using
H&E confirmed the presence of a large primary mammary tumor (T) 32 days
after 4T1.2 mouse mammary tumor cell injection into the fourth mammary
fat pad of female BALB/c mice. High OSM expression is seen in the tumor,
as is background expression in the normal breast connective tissue (CT).
OSM expression is shown to be highest in the invasive edge of the
tumor (T) closest to the normal breast connective tissue (CT). Control
slides with no primary OSM antibody show low background staining.
(PPTX 315 kb)
Additional file 6: Figure S5. qPCR analysis of lung metastases after
intracardiac injections. 4T1.2-shLacZ cells and 4T1.2-shOSM2 cells were
introduced via intracardiac injection, and qPCR analysis of the lung
metastases indicated that the difference between the groups was not
significant by two-tailed Student’s t test. (ZIP 60 kb)
Additional file 7: Figure S6. Control colony-forming assay results de-
rived from non-tumor-bearing mice. Blood from non-tumor-bearing mice
contained no cells that formed colonies. (PPTX 53 kb)
Additional file 8: Figure S7. Test of cell line-specific variance in colony-
forming assay between 4T1.2-shLacZ and 4T1.2-shOSM2 cell lines. Ap-
proximately 10 and 50 cells of 4T1.2-shLacZ or 4T1.2-shOSM2 cells were
seeded onto tissue culture plates and were allowed to incubate until col-
ony formation. No significant differences between the cells were de-
tected with ~ 10 cells seeded; however, there was a small but significant
increase in the number of colonies with 4T1.2-shOSM2 cells at 50 cells
seeded. Data are expressed as mean ± SEM. *p < 0.05 by one-way ANOVA
with Bonferroni’s multiple comparisons test. (PPTX 68 kb)
Additional file 9: Figure S8. OSM inhibits proliferation of 4T1.2 cells.
One hundred 4T1.2 cells were plated at day 0 and treated with 25 ng/ml
of OSM. By day 7, there was a 20% reduction in total cell numbers in the
OSM-treated group versus the non-OSM-treated group. Data are
expressed as mean ± SEM. *p < 0.05, **p < 0.01; statistical analysis was
performed for each day using a two-tailed Student’s t test. (PPTX 21 kb)
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